Xtant Medical Holdings, Inc. · AMEX:XTNT
Xtant Medical — Q1 2025 Earnings Presentation
17 slides from Xtant Medical's earnings presentation, May 12, 2025
Slide 1: Investor Presentation
www.xtantmedical.com Investor Presentation May 2025
Slide 2: Disclosure Statements
D I S C L O S U R E S T A T EM E N T S Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that are predictive in nat
Slide 3: Investment Highlights
I N V ES T M EN T H I G H L I G H T S Xtant Medical is a global medical technology company focused on the design, development and commercialization of biologics and spinal implant systems 1. Large Market Opportunity 2. Revenue Growth 3. Profitable $10 Billion Worldwide Spine FY2024 Revenue: $117.3M
Slide 4: The Turnaround – Re-Engineered for Growth
T H E T U R N A R OU N D – R E - EN G I N E ER E D FOR GROWTH Business has been completely overhauled 2025 2024 Fully vertically integrated in all Expanded R&D 2023 capabilities to five 1999 internally produce orthobiologic Acquired Coflex Bacterin Biologics 2022 outsourced categories founde
Slide 5: Xtant's Full-Service Product Offering
X T A N T ' S F U L L - S E R VI CE P R O D U C T O F F E R I N G Milled Cervical Grafts Fusion Demineralized Bone Matrix Posterior Thoracic Fusion/ Thoracic Lumbar Traditional Grafts Viable Bone Matrix TLIF/PLIF/ALIF Lumbar Fusion Growth Factor Amnio Membrane Allografts Sacroiliac Fusion BIOLOGICS
Slide 6: Global Spine and Orthobiologic Market
G L O B A L S P I N E A N D O R T H O B I O L OG I C M A R K ET Significant market opportunity both domestically and internationally with a 5% CAGR Total WW market: $10.1B Total US market: $8.1B ORTHOBIOLOGICS: $2.5B SPINAL IMPLANTS: $5.6B Source: Markets and Markets & iData US Market Report Suite f
Slide 7: U.S. Orthobiologic Market
U . S . O R T H O BI OL O G I C M A R K ET Xtant is one of the few orthobiologics companies that offers ALL FIVE product lines $2.5B Xtant’s current portfolio addresses the entire Demineralized $485M market of $2.5B Bone Graft Demineralized Bone Graft Cellular Allograft Allograft $163M Allogra
Slide 8: Coflex: Interlaminar Stabilization Device
C O F L E X: I N T E RL A M I N A R S T A B I L I Z A T I O N D E V I CE Non-fusion, motion preserving solution clinically proven to dynamically stabilize anatomical forces where lumbar spinal stenosis exists Dynamic Design Unique u-shaped design enables it to be placed further anterior than tradi
Slide 9: Achieving Robust Revenue Growth
A C H I EV I N G R O B U S T $126M-$130M REVENUE GROWTH $117.5M Revenue growth through 2024 driven by combination of core biologics offering and +9% recent acquisitions. $91.3M +29% 2025 estimated revenue growth is 100% organic +58% $55M $58M $51M Growth includes revenue from 100% recent acquisition
Slide 10: Growth Strategy Pillars
G R O W T H S T R A T E GY P I L L A R S XTANT MEDICAL GROWTH STRATEGY Expand New Leverage Access & M&A Product Adjacent Distribution Activity Flow Markets Network Drive new Utilize R&D Sell deeper and Acquire best in innovations and engine and Bio- broader – become a class technologies distributor
Slide 11: Pillar One: Phase-Vertical Integration
P I L L A R O N E : P H A S E 1 - V E R T I CA L I N T E G R A T I O N IMPROVING MARGIN PROFILE & SELF-SUSTAINABILITY Moving from lower margin manufacturing to higher margin $400/CC Growth Factor Viable Bone Matrix Amnion Price Synthetics Demineralized Bone Allograft $100/CC 50% Gross Margin % 90% 1
Slide 12: Pillar One: Phase – DBM Reinvigoration
P I L L A R O N E : P H A S E 2 – D B M R E I N V I G OR A T I O N IMPROVING TECHNOLOGY AND MARGIN PROFILE OF BASE DBM BUSINESS $400/CC Growth Factor Viable Bone Enhanced Matrix DBM Amnion Price Synthetics Demineralized Bone Allograft $100/CC 50% Gross Margin % 90% 12
Slide 13: Near-Term Pipeline
N E A R- T ER M P I P E L I N E Overarching Strategy • Upgrade biologics performance of outsourced products through best in class internally developed technology • Increase product margin and profitability through vertical integration • Control supply and prevent backorders by leveraging bio-manufac
Slide 14: Pillar Two: Grow Adjacent Markets
P I L L A R T W O : G R O W A D JA C E N T M A R K E T S NERVE HEMOSTATIC REGENERATION BIOLOGICS ($2.2B) ($1.2B) CHRONIC WOUND ORTHOBIOLOGICS SPORTS CARE TISSUE BANK MEDICINE ($2.5B) ($2.5B) ($7.2B) ANTIMICROBIAL SURGICAL BIOLOGICS REPAIR ($500M+) ($7.2B) 14
Slide 15: Pillar Three: Expand Distribution Network
PILLAR THREE: EXPAND DISTRIBUTION NETWORK STEP ONE: Increase Contractual Access Continue to sign new IDN and GPO agreement Expand current contracts to include all recently introduced products STEP TWO: Build National Network Open Distribution Model: Continue to attract and sign additional Independ
Slide 16: Pillar Four: Robust Acquisition Pipeline “3-C’s”
PILLAR FOUR: ROBUST ACQUISITION PIPELINE “3-C’s” Capabilities Capacity Cashflows Inorganic Growth is Key to Longer-term Biologics Profitable as Achieving Long-Term Goals higher end production meets standalone Positioning in orthobiologics and regenerative robust current and businesses spine business
Slide 17: IR Contact
IR Contact: Brett Maas Brett@Haydenir.com 480-861-2425
Xtant Medical Holdings — Q1 2025 Earnings Presentation on 6ix